#United States #Los Angeles #Alzheimer's Disease #Neuraceq #Life Molecular Imaging

Expansion of Neuraceq® Production in Southern California

Life Molecular Imaging (LMI), a company under Lantheus, has made significant strides in improving the accessibility of its innovative PET radiopharmaceutical, Neuraceq® (florbetaben F-18 injection), by expanding its production and distribution in Southern California. This expansion, crucially impacting areas such as San Diego, aims to make the diagnostic agent more widely available to imaging centers, healthcare providers, and patients experiencing cognitive decline.

On August 13, 2025, the first batch from a newly equipped production facility in Los Angeles was delivered, marking a vital milestone in the company’s mission to enhance patient care and diagnostics in the region. The introduction of Neuraceq® provides a powerful tool for diagnosing Alzheimer's disease, enabling medical professionals to detect amyloid plaques in the brains of adult patients suffering from cognitive impairment. The FDA has approved Neuraceq® for this specific purpose, setting a new standard in the evaluation of Alzheimer’s and other cognitive disorders.

Neuraceq® plays an essential role in assisting neurologists in characterizing patients for new anti-amyloid medications. As the medical landscape evolves, the demand for reliable amyloid PET imaging is skyrocketing, positioning Neuraceq® as a crucial component in the treatment framework for Alzheimer’s disease.

Colleen Ruby, the US Country Head and COO of LMI, expressed the company's commitment to enhancing geographic access to Neuraceq® for those navigating the complexities of Alzheimer’s treatment. "As the adoption of anti-amyloid therapies increases, so does the necessity for dependable imaging to support treatment decisions. Our new facility in Los Angeles is pivotal in meeting this growing need," she stated, underscoring LMI’s commitment to high-quality diagnostic solutions tailored to neurologists and patients.

What is Neuraceq®?

Neuraceq® (florbetaben F-18) is classified as a radioactive diagnostic drug designed for positron emission tomography (PET) of the brain. It helps estimate the density of amyloid beta neuritic plaques in adults diagnosed with cognitive impairment, especially in the context of Alzheimer’s disease and related cognitive decline causes.

One significant point is that there are no contraindications for the use of Neuraceq®, but healthcare providers must remain vigilant about the potential for image misinterpretation and other errors. Moreover, like all radiopharmaceuticals, Neuraceq® contributes to a patient’s overall radiation exposure, which imposes a long-term risk. Consequently, both patients and healthcare workers need to uphold the highest safety standards during handling and administration.

Ongoing Commitment to Patients

This recent expansion aligns with LMI’s overarching goal of advancing diagnostic access, improving outcomes for Alzheimer’s patients, and ultimately enhancing their quality of life. With an unyielding focus on innovation and patient-centric care, Life Molecular Imaging aims to establish itself as a leading force in the development of cutting-edge PET imaging solutions.

As LMI continues to forge pathways in the molecular imaging landscape, the future resale of Neuraceq® across California seems promising. This move showcases how the company is addressing the rising demand for diagnostic tools in the healthcare sector. For more information on Neuraceq®, visit Neuraceq.com.

About Life Molecular Imaging

Life Molecular Imaging is dedicated to advancing healthcare through the development of state-of-the-art PET radiopharmaceuticals, focusing on neurodegenerative and cardiovascular diseases. Its mission is to enhance early detection and treatment outcomes by harnessing the power of molecular imaging technologies. For more information about LMI and its innovative products, visit life-mi.com.

Contact Information

For further media inquiries, contact:

• - Media Contact: Melissa Downs
• - Title: Executive Director, External Communications
• - Phone: 646-975-2533

Conclusion

The expansion of Neuraceq® production in Southern California represents a significant leap forward in addressing the critical needs of Alzheimer’s diagnostics, reflecting Life Molecular Imaging’s commitment to improving patient care in the cognitive health sector.